Is Xeris Biopharma Holdings, Inc. (XERS) a Buy, Sell, or Hold?
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
$8.28 USD
$0.12 (1.47%)
- Volume
- 1.22M
- Average Volume
- 1.86M
- Market Capitalization
- $1.43B
- P/E Ratio
- 116.95
- Dividend Yield
- 0.00%
- Price Target
- $6.60
- Year High
- $10.08
- Year Low
- $4.87
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.12
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | John Shannon |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | XERS |
| CUSIP | 98422E103 |
| CIK | 0001867096 |
| Web | https://www.xerispharma.com |
| Phone | 844 445 5704 |
| Currency | USD |
| Employees | 435 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 2.87 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.12 |
| Quick Ratio | 1.50 |
| Cash Ratio | 0.94 |
Sales & Book Value
| Annual Sales | $291.84M |
| Price / Sales | 4.54 |
| Cash Flow | 0.28 |
| Price / Cash Flow | 30.27 |
| Price / Book | 108.52 |
Price Target and Rating
| Average Stock Price Forecast | $6.60 |
| High Stock Price Forecast | $18.00 |
| Low Stock Price Forecast | $4.00 |
| Forecast Upside/Downside | 25.45% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $0.0032 |
| Trailing P/E Ratio | 116.95 |
| PEG Ratio | 0.01 |
| P/E Growth | 0.01 |
| Net Income | $554K |
| Net Margin | 3.81% |
| Pretax Margin | 3.81% |
| Return on Equity | 735.00% |
| Return on Assets | 3.06% |
Financials Score
| AltmanZ Score | 1.33 |
| Piotroski Score | 7.00 |
| Working Capital | 133.09M |
| Total Assets | 392.01M |
| Ebit | 33.52M |
| Market Cap | 1.41B |
| Total Liabilities | 379M |
Poll Results
About Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals lev ... eraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?
2026-07-08 11:40:21
Xeris Biopharma (XERS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-07-02 23:00:00
Please replace the release issued earlier today with the following corrected version that provides additional information regarding the inducement grants. Th
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-07-02 22:40:00
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Please replace the release issued earlier today with the following corrected version that provides additional information regarding the inducement grants. The corrected release reads: XERIS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today anno.
Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-07-02 16:05:00
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 221,323 shares of its common stock to 47 new employees under Xeris' Inducement Equity Plan. Xeris' Inducement Equity Pla.
Xeris Announces Updates to Its Board of Directors
2026-06-30 07:00:00
CHICAGO--(BUSINESS WIRE)--Xeris Announces Updates to Its Board of Directors.
2026-06-11 16:39:00
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that today the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance with respect to U.S. Patent Application No. 17/151,405, entitled “Compositions and Methods of Use.” The a.
Xeris Biopharma Announces Private Exchange of Convertible Notes
2026-06-11 08:00:00
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing
Xeris Biopharma Announces Private Exchange of Convertible Notes
2026-06-11 07:00:00
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 8.00% Convertible Senior Notes due 2028 (the “Notes”). Pursuant to the exchange agreements, Xeris has agreed, subject to customary closing condit.
Frequently Asked Questions
-
What is the current Xeris Biopharma Holdings, Inc. (XERS) stock price?
-
Xeris Biopharma Holdings, Inc.(NASDAQ:XERS) stock price is $8.28 in the last trading session. During the trading session, XERS stock reached the peak price of $10.08 while $4.87 was the lowest point it dropped to. The percentage change in XERS stock occurred in the recent session was 1.47% while the dollar amount for the price change in XERS stock was $0.12.
-
XERS's industry and sector of operation?
-
The NASDAQ listed XERS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of XERS?
-
John Shannon | Chairman & CEO
Beth Hecht | Chief Legal Officer & Corporate Secretary
Anh Nguyen | Chief Medical Officer
Brian Conner | SVP of Quality and Chief Compliance & Risk Officer
Steven Pieper | Chief Financial Officer -
How many employees does XERS have?
-
Number of XERS employees currently stands at 435. XERS operates from 180 North LaSalle Street, Chicago, IL 60601, US.
-
Link for XERS official website?
-
Official Website of XERS is: https://www.xerispharma.com
-
How do I contact XERS?
-
XERS could be contacted at phone #844 445 5704 and can also be accessed through its website. XERS operates from 180 North LaSalle Street, Chicago, IL 60601, US.
-
How many shares of XERS are traded daily?
-
The average number of XERS shares traded daily for last 3 months was 1.86M.
-
What is the market cap of XERS currently?
-
The market value of XERS currently stands at $1.43B with its latest stock price at $8.28